IUL gains momentum in 2020 and prepares the launch of a new test reader

The Spanish company IUL Instruments which designs, produces, and markets automation products for microbiology laboratories, has increased its turnover by 2% in 2020 compared to the previous year, to $4.5 million (€3.7 million). 

In September, IUL Instruments started to market a reader that facilitates the screening of new cases of coronavirus and is preparing to launch a new reader on the market. The company, based in Barcelona, has designed a reader that allows quantitative or qualitative results to be obtained and large-scale studies to be carried out to monitor immunity to Covid-19. The product is already marketed in the United States, Belgium, Italy, Singapore, and Taiwan. 

If you want to find more details about IUL Instruments and its Covid-19 test, download for free the Born2Invest mobile app. Our companion app keeps its readers up to date with the latest business news in the world.

The new product is manufactured with 3D printers

The company has allocated $727,000 (€600,000) to the production of this reader, which is manufactured with 3D printers. The reader can be adapted to various tests, such as antigens or antibodies, as well as different diseases such as diabetes. Up to twenty pharmaceutical and biotechnological companies have been interested in the product to sell it together with their test. 

IUL Instruments started working on the reader six years ago to diagnose diseases of cats and dogs and in the last months has adapted the software, the data export process and its security.  IUL started to market the Covid-19 test reader in September. The technology of this product allows to obtain results by increasing the sensitivity in the reading of rapid tests. This facilitates the traceability of the Covid-19 cases and the massive screening in places like hospitals, airports and pharmacies without the need of health professionals or qualified personnel. IUL has expanded the capacity of its facilities to 5,000 square meters. 

The company has increased by 25% the productive space of the fourth floor of its building, up to 75%, and still retains its old headquarters of 2,000 square meters in case demand continues to increase. The company is already preparing the launch of a larger reader that will allow more molecules to be read. In addition, the range of detecting diseases of this product will be greater and will be on the market in a month. 

However, IUL expects to register a turnover in 2021 similar to that of the previous year.  Up to twenty pharmaceutical and biotechnological companies are testing the test to market it. IUL currently sells 92.5% of its products abroad and allocates 13% of its turnover to research and development. Vicenç Font is the CEO of the company and his family and another partner maintain the ownership. The company, founded in 1987, aims to provide a more convenient and safer microbiological control for industry and health. IUL markets its products in more than one hundred countries and has a staff of forty workers.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.